CoChat
Sign Up
Cited by 34Mesenchymal stem cell researchCancer Research and TreatmentsImmunotherapy and Immune Responses

Mesenchymal stem cells - the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists

Open access
Minev, Theia, Balbuena, Shani, Gill, Jaya Mini, Marincola, Francesco M., Kesari, Santosh, Lin, Feng·2024·Oncotarget
DOI 10.18632/oncotarget.28672PMC PMC11584032
Open this paper in CoChat — free accountOpen PDF

Abstract

// Theia Minev 1 , Shani Balbuena 1 , Jaya Mini Gill 1 , Francesco M. Marincola 2 , Santosh Kesari 3 and Feng Lin 1 1 CureScience Institute, San Diego, CA 92121, USA 2 Sonata Therapeutics, Boston, MA 02472, USA 3 Department of Translational Neurosciences, Pacific Neuroscience Institute and Providence Saint John’s Health Center, Saint John’s Cancer Institute, Santa Monica, CA 90404, USA Correspondence to: Feng Lin, email: flin@curescience.org Keywords: mesenchymal stem cells; genetic engineering; cancer immunotherapy; mesenchymal stem cell homing; stem cell delivery Received: August 20, 2024 Accepted: November 05, 2024 Published: November 22, 2024 Copyright: © 2024 Minev et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Mesenchymal stem cells (MSCs) are recognized for their immunomodulatory capabilities, tumor-homing abilities, and capacity to serve as carriers for therapeutic agents. This review delves into the role of adoptively transferred MSCs in tumor progression, their interactions with the tumor microenvironment, and their use in delivering anti-cancer drugs, oncolytic viruses, and genetic material. It also addresses the challenges and limitations associated with MSC therapy, such as variability in MSC preparations and potential tumorigenic effects emphasizing the need for advanced genetic engineering and personalized approaches to enhance therapeutic efficacy. The review concludes with an optimistic outlook on the future of MSC-based therapies, underscoring their promise to develop effective and personalized cancer treatments.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.28672

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mesenchymal stem cells have demonstrated the ability to mediate resistance to chemotherapy and other treatments.

    “Moreover, MSCs have demonstrated the ability to mediate resistance to chemotherapy and other treatments, thereby complicating therapeutic strategies [8, 9].”

    From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [8]

    The sections on MSC-induced immunosuppression and tumor growth promotion say MSCs can protect tumors and complicate cancer therapy. However, the Introduction attributes resistance to chemotherapy and other conventional treatments to cancer biology, not to MSCs; our copy does not establish MSC-mediated treatment resistance. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 75

  1. [1]Hu J, Ascierto P, Cesano A, Herrmann V, Marincola FM. Shifting the paradigm: engaging multicellular networks for cancer therapy. J Transl Med. 2024; 22: 270. 10.1186/s12967-024-05043-8. 38475820 PMC10936124 · DOI
  2. [2]Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018; 359: 1350– 55. 10.1126/science.aar4060. 29567705 PMC7391259 · DOI · Paper page
  3. [3]Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023; 614: 635– 48. 10.1038/s41586-023-05707-3. 36813894 · DOI
  4. [4]Amorós-Pérez B, Rivas-Pardo B, Gómez Del Moral M, Subiza JL, Martínez-Naves E. State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future? Cells. 2024; 13: 725. 10.3390/cells13090725. 38727261 PMC11083689 · DOI
  5. [5]Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013; 39: 38– 48. 10.1016/j.immuni.2013.07.004. 23890062 PMC3788678 · DOI · Paper page
  6. [6]Shapiro MA. Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer. Front Oncol. 2024; 14: 1379738. 10.3389/fonc.2024.1379738. 38746685 PMC11091260 · DOI
  7. [7]Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235– 42. 10.1056/NEJMoa011795. 11807147 · DOI · Paper page
  8. [8]Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8: 315– 7. 10.1080/14653240600855905. 16923606 · DOI · Paper page
  9. [9]Mushahary D, Spittler A, Kasper C, Weber V, Charwat V. Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytometry A. 2018; 93: 19– 31. 10.1002/cyto.a.23242. 29072818 · DOI
  10. [10]Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011; 9: 11– 5. 10.1016/j.stem.2011.06.008. 21726829 PMC3144500 · DOI · Paper page
  11. [11]Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008; 8: 726– 36. 10.1038/nri2395. 19172693 · DOI
  12. [12]Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One. 2010; 5: e10088. 10.1371/journal.pone.0010088. 20436665 PMC2859930 · DOI · Paper page
  13. [13]Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood. 2005; 105: 2821– 7. 10.1182/blood-2004-09-3696. 15591115 · DOI
  14. [14]Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004; 103: 4619– 21. 10.1182/blood-2003-11-3909. 15001472 · DOI
  15. [15]Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008; 111: 1327– 33. 10.1182/blood-2007-02-074997. 17951526 · DOI
  16. [16]Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002; 99: 3838– 43. 10.1182/blood.v99.10.3838. 11986244 · DOI · Paper page
  17. [17]Boissel L, Tuncer HH, Betancur M, Wolfberg A, Klingemann H. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol Blood Marrow Transplant. 2008; 14: 1031– 38. 10.1016/j.bbmt.2008.06.016. 18721766 · DOI
  18. [18]He Y, Qu Y, Meng B, Huang W, Tang J, Wang R, Chen Z, Kou X, Shi S. Mesenchymal stem cells empower T cells in the lymph nodes via MCP-1/PD-L1 axis. Cell Death Dis. 2022; 13: 365. 10.1038/s41419-022-04822-9. 35436982 PMC9016066 · DOI
  19. [19]Jin P, Zhao Y, Liu H, Chen J, Ren J, Jin J, Bedognetti D, Liu S, Wang E, Marincola F, Stroncek D. Interferon-γ and Tumor Necrosis Factor-α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype. Sci Rep. 2016; 6: 26345. 10.1038/srep26345. 27211104 PMC4876328 · DOI
  20. [20]Liang W, Chen X, Zhang S, Fang J, Chen M, Xu Y, Chen X. Mesenchymal stem cells as a double-edged sword in tumor growth: focusing on MSC-derived cytokines. Cell Mol Biol Lett. 2021; 26: 3. 10.1186/s11658-020-00246-5. 33472580 PMC7818947 · DOI
  21. [21]Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002; 62: 3603– 8. 12097260
  22. [22]Moreno R. Mesenchymal stem cells and oncolytic viruses: joining forces against cancer. J Immunother Cancer. 2021; 9: e001684. 10.1136/jitc-2020-001684. 33558278 PMC7871674 · DOI
  23. [23]Le Blanc K, Davies LC. MSCs-cells with many sides. Cytotherapy. 2018; 20: 273– 78. 10.1016/j.jcyt.2018.01.009. 29434007 · DOI
  24. [24]Petrella F, Cassina EM, Libretti L, Pirondini E, Raveglia F, Tuoro A. Stem cell technology for antitumor drug loading and delivery in oncology. Oncol Res. 2024; 32: 433– 37. 10.32604/or.2023.046497. 38361752 PMC10865768 · DOI
  25. [25]Sohni A, Verfaillie CM. Mesenchymal stem cells migration homing and tracking. Stem Cells Int. 2013; 2013: 130763. 10.1155/2013/130763. 24194766 PMC3806396 · DOI
  26. [26]Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells. 2006; 24: 1030– 41. 10.1634/stemcells.2005-0319. 16253981 · DOI · Paper page
  27. [27]Yan C, Song X, Yu W, Wei F, Li H, Lv M, Zhang X, Ren X. Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects. Tumour Biol. 2016; 37: 8425– 35. 10.1007/s13277-015-4746-7. 26733169 · DOI
  28. [28]Yoshimura T, Li C, Wang Y, Matsukawa A. The chemokine monocyte chemoattractant protein-1/CCL2 is a promoter of breast cancer metastasis. Cell Mol Immunol. 2023; 20: 714– 38. 10.1038/s41423-023-01013-0. 37208442 PMC10310763 · DOI
  29. [29]She S, Ren L, Chen P, Wang M, Chen D, Wang Y, Chen H. Functional Roles of Chemokine Receptor CCR2 and Its Ligands in Liver Disease. Front Immunol. 2022; 13: 812431. 10.3389/fimmu.2022.812431. 35281057 PMC8913720 · DOI
  30. [30]Méndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, Scadden DT, Ma’ayan A, Enikolopov GN, Frenette PS. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010; 466: 829– 34. 10.1038/nature09262. 20703299 PMC3146551 · DOI
  31. [31]Cuiffo BG, Karnoub AE. Mesenchymal stem cells in tumor development: emerging roles and concepts. Cell Adh Migr. 2012; 6: 220– 30. 10.4161/cam.20875. 22863739 PMC3427236 · DOI
  32. [32]Han Y, Yang J, Fang J, Zhou Y, Candi E, Wang J, Hua D, Shao C, Shi Y. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct Target Ther. 2022; 7: 92. 10.1038/s41392-022-00932-0. 35314676 PMC8935608 · DOI · Paper page
  33. [33]Al-Kharboosh R, ReFaey K, Lara-Velazquez M, Grewal SS, Imitola J, Quiñones-Hinojosa A. Inflammatory Mediators in Glioma Microenvironment Play a Dual Role in Gliomagenesis and Mesenchymal Stem Cell Homing: Implication for Cellular Therapy. Mayo Clin Proc Innov Qual Outcomes. 2020; 4: 443– 59. 10.1016/j.mayocpiqo.2020.04.006. 32793872 PMC7411162 · DOI
  34. [34]Prabha S, Merali C, Sehgal D, Nicolas E, Bhaskar N, Flores M, Bhatnagar S, Nethi SK, Barrero CA, Merali S, Panyam J. Incorporation of paclitaxel in mesenchymal stem cells using nanoengineering upregulates antioxidant response, CXCR4 expression and enhances tumor homing. Mater Today Bio. 2023; 19: 100567. 10.1016/j.mtbio.2023.100567. 36747581 PMC9898454 · DOI
  35. [35]Wang X, Gao J, Ouyang X, Wang J, Sun X, Lv Y. Mesenchymal stem cells loaded with paclitaxel-poly(lactic-co-glycolic acid) nanoparticles for glioma-targeting therapy. Int J Nanomedicine. 2018; 13: 5231– 48. 10.2147/IJN.S167142. 30237710 PMC6136913 · DOI
  36. [36]Mahasa KJ, de Pillis L, Ouifki R, Eladdadi A, Maini P, Yoon AR, Yun CO. Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy. Sci Rep. 2020; 10: 425. 10.1038/s41598-019-57240-x. 31949228 PMC6965634 · DOI
  37. [37]Najar M, Raicevic G, Fayyad-Kazan H, Bron D, Toungouz M, Lagneaux L. Mesenchymal stromal cells and immunomodulation: A gathering of regulatory immune cells. Cytotherapy. 2016; 18: 160– 71. 10.1016/j.jcyt.2015.10.011. 26794710 · DOI
  38. [39]Poomani MS, Mariappan I, Perumal R, Regurajan R, Muthan K, Subramanian V. Mesenchymal Stem Cell (MSCs) Therapy for Ischemic Heart Disease: A Promising Frontier. Glob Heart. 2022; 17: 19. 10.5334/gh.1098. 35342702 PMC8916054 · DOI
  39. [40]Hoogduijn MJ, Crop MJ, Peeters AM, Korevaar SS, Eijken M, Drabbels JJ, Roelen DL, Maat AP, Balk AH, Weimar W, Baan CC. Donor-derived mesenchymal stem cells remain present and functional in the transplanted human heart. Am J Transplant. 2009; 9: 222– 30. 10.1111/j.1600-6143.2008.02450.x. 18976299 · DOI
  40. [41]Walter MN, Wright KT, Fuller HR, MacNeil S, Johnson WE. Mesenchymal stem cell-conditioned medium accelerates skin wound healing: an in vitro study of fibroblast and keratinocyte scratch assays. Exp Cell Res. 2010; 316: 1271– 81. 10.1016/j.yexcr.2010.02.026. 20206158 · DOI
  41. [43]Liu P, Chen M, Liu Y, Qi LS, Ding S. CRISPR-Based Chromatin Remodeling of the Endogenous Oct4 or Sox2 Locus Enables Reprogramming to Pluripotency. Cell Stem Cell. 2018; 22: 252– 61.e4. 10.1016/j.stem.2017.12.001. 29358044 · DOI
  42. [44]Yu C, Liu Y, Ma T, Liu K, Xu S, Zhang Y, Liu H, La Russa M, Xie M, Ding S, Qi LS. Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell. 2015; 16: 142– 7. 10.1016/j.stem.2015.01.003. 25658371 PMC4461869 · DOI · Paper page
  43. [45]Wang H, Xu X, Nguyen CM, Liu Y, Gao Y, Lin X, Daley T, Kipniss NH, La Russa M, Qi LS. CRISPR-Mediated Programmable 3D Genome Positioning and Nuclear Organization. Cell. 2018; 175: 1405– 17.e14. 10.1016/j.cell.2018.09.013. 30318144 PMC6239909 · DOI
  44. [46]Kułach N, Pilny E, Cichoń T, Czapla J, Jarosz-Biej M, Rusin M, Drzyzga A, Matuszczak S, Szala S, Smolarczyk R. Mesenchymal stromal cells as carriers of IL-12 reduce primary and metastatic tumors of murine melanoma. Sci Rep. 2021; 11: 18335. 10.1038/s41598-021-97435-9. 34526531 PMC8443548 · DOI
  45. [47]Ahn JO, Lee HW, Seo KW, Kang SK, Ra JC, Youn HY. Anti-tumor effect of adipose tissue derived-mesenchymal stem cells expressing interferon-β and treatment with cisplatin in a xenograft mouse model for canine melanoma. PLoS One. 2013; 8: e74897. 10.1371/journal.pone.0074897. 24040358 PMC3767623 · DOI
  46. [48]Coccè V, Bonomi A, Cavicchini L, Sisto F, Giannì A, Farronato G, Alessandri G, Petrella F, Sordi V, Parati E, Bondiolotti G, Paino F, Pessina A. Paclitaxel Priming of TRAIL Expressing Mesenchymal Stromal Cells (MSCs-TRAIL) Increases Antitumor Efficacy of Their Secretome. Curr Cancer Drug Targets. 2020. [Epub ahead of print]. 10.2174/1568009620666201116112153. 33200709 · DOI
  47. [49]Spano C, Grisendi G, Golinelli G, Rossignoli F, Prapa M, Bestagno M, Candini O, Petrachi T, Recchia A, Miselli F, Rovesti G, Orsi G, Maiorana A, et al. Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Sci Rep. 2019; 9: 1788. 10.1038/s41598-018-37433-6. 30742129 PMC6370785 · DOI
  48. [50]Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, Russell SJ, Dietz AB, Peng KW. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res. 2009; 15: 7246– 55. 10.1158/1078-0432.CCR-09-1292. 19934299 PMC2787715 · DOI
  49. [51]Parker Kerrigan BC, Shimizu Y, Andreeff M, Lang FF. Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas. Cytotherapy. 2017; 19: 445– 57. 10.1016/j.jcyt.2017.02.002. 28233640 PMC5410175 · DOI
  50. [52]Frank RT, Edmiston M, Kendall SE, Najbauer J, Cheung CW, Kassa T, Metz MZ, Kim SU, Glackin CA, Wu AM, Yazaki PJ, Aboody KS. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS One. 2009; 4: e8314. 10.1371/journal.pone.0008314. 20016813 PMC2789379 · DOI
  51. [53]Fares J, Ahmed AU, Ulasov IV, Sonabend AM, Miska J, Lee-Chang C, Balyasnikova IV, Chandler JP, Portnow J, Tate MC, Kumthekar P, Lukas RV, Grimm SA, et al. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. Lancet Oncol. 2021; 22: 1103– 14. 10.1016/S1470-2045(21)00245-X. 34214495 PMC8328944 · DOI
  52. [54]Kou M, Huang L, Yang J, Chiang Z, Chen S, Liu J, Guo L, Zhang X, Zhou X, Xu X, Yan X, Wang Y, Zhang J, et al. Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool? Cell Death Dis. 2022; 13: 580. 10.1038/s41419-022-05034-x. 35787632 PMC9252569 · DOI
  53. [55]Phinney DG, Pittenger MF. Concise Review: MSC-Derived Exosomes for Cell-Free Therapy. Stem Cells. 2017; 35: 851– 58. 10.1002/stem.2575. 28294454 · DOI · Paper page
  54. [56]Zhang H, Wang S, Sun M, Cui Y, Xing J, Teng L, Xi Z, Yang Z. Exosomes as smart drug delivery vehicles for cancer immunotherapy. Front Immunol. 2023; 13: 1093607. 10.3389/fimmu.2022.1093607. 36733388 PMC9888251 · DOI
  55. [57]Moon B, Chang S. Exosome as a Delivery Vehicle for Cancer Therapy. Cells. 2022; 11: 316. 10.3390/cells11030316. 35159126 PMC8834560 · DOI
  56. [58]Shen Z, Huang W, Liu J, Tian J, Wang S, Rui K. Effects of Mesenchymal Stem Cell-Derived Exosomes on Autoimmune Diseases. Front Immunol. 2021; 12: 749192. 10.3389/fimmu.2021.749192. 34646275 PMC8503317 · DOI
  57. [59]Rivera-Cruz CM, Shearer JJ, Figueiredo Neto M, Figueiredo ML. The Immunomodulatory Effects of Mesenchymal Stem Cell Polarization within the Tumor Microenvironment Niche. Stem Cells Int. 2017; 2017: 4015039. 10.1155/2017/4015039. 29181035 PMC5664329 · DOI
  58. [60]Takigawa H, Kitadai Y, Shinagawa K, Yuge R, Higashi Y, Tanaka S, Yasui W, Chayama K. Mesenchymal Stem Cells Induce Epithelial to Mesenchymal Transition in Colon Cancer Cells through Direct Cell-to-Cell Contact. Neoplasia. 2017; 19: 429– 38. 10.1016/j.neo.2017.02.010. 28433772 PMC5402629 · DOI
  59. [61]Roobrouck VD, Vanuytsel K, Verfaillie CM. Concise review: culture mediated changes in fate and/or potency of stem cells. Stem Cells. 2011; 29: 583– 9. 10.1002/stem.603. 21305670 · DOI
  60. [62]Murray IR, Corselli M, Petrigliano FA, Soo C, Péault B. Recent insights into the identity of mesenchymal stem cells: Implications for orthopaedic applications. Bone Joint J. 2014; 96-B:291–98. 10.1302/0301-620X.96B3.32789. 24589781 · DOI
  61. [63]Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, Armstrong L, Djonov V, Lako M, Stojkovic M. Ethical and Safety Issues of Stem Cell-Based Therapy. Int J Med Sci. 2018; 15: 36– 45. 10.7150/ijms.21666. 29333086 PMC5765738 · DOI
  62. [64]Rady D, Abbass MMS, El-Rashidy AA, El Moshy S, Radwan IA, Dörfer CE, Fawzy El-Sayed KM. Mesenchymal Stem/Progenitor Cells: The Prospect of Human Clinical Translation. Stem Cells Int. 2020; 2020: 8837654. 10.1155/2020/8837654. 33953753 PMC8063852 · DOI
  63. [65]Mianné J, Bourguignon C, Nguyen Van C, Fieldès M, Nasri A, Assou S, De Vos J. Pipeline for the Generation and Characterization of Transgenic Human Pluripotent Stem Cells Using the CRISPR/Cas9 Technology. Cells. 2020; 9: 1312. 10.3390/cells9051312. 32466123 PMC7290981 · DOI
  64. [66]González F. CRISPR/Cas9 genome editing in human pluripotent stem cells: Harnessing human genetics in a dish. Dev Dyn. 2016; 245: 788– 06. 10.1002/dvdy.24414. 27145095 · DOI
  65. [67]Lotfy A, Wang H. Immune Checkpoint Inhibitors and Mesenchymal Stem/Stromal Cells Combination Therapy Might Offer a Promising Treatment Option for Cancer. Stem Cell Rev Rep. 2023; 19: 823– 24. 10.1007/s12015-022-10474-1. 36454388 PMC10143520 · DOI
  66. [68]Yan L, Li J, Zhang C. The role of MSCs and CAR-MSCs in cellular immunotherapy. Cell Commun Signal. 2023; 21: 187. 10.1186/s12964-023-01191-4. 37528472 PMC10391838 · DOI
  67. [69]Ito S, Sato T, Maeta T. Role and Therapeutic Targeting of SDF-1α/CXCR4 Axis in Multiple Myeloma. Cancers (Basel). 2021; 13: 1793. 10.3390/cancers13081793. 33918655 PMC8069569 · DOI
  68. [70]Liu J, Qu S, Zhang T, Gao Y, Shi H, Song K, Chen W, Yin W. Applications of Single-Cell Omics in Tumor Immunology. Front Immunol. 2021; 12: 697412. 10.3389/fimmu.2021.697412. 34177965 PMC8221107 · DOI
  69. [71]Sun XY, Nong J, Qin K, Warnock GL, Dai LJ. Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine. World J Stem Cells. 2011; 3: 96– 103. 10.4252/wjsc.v3.i11.96. 22180830 PMC3240679 · DOI
  70. [72]Sun L, Yao Y. Mesenchymal stem/stromal cells-a principal element for tumour microenvironment heterogeneity. Front Immunol. 2023; 14: 1274379. 10.3389/fimmu.2023.1274379. 37885883 PMC10599013 · DOI
  71. [73]Ridge SM, Sullivan FJ, Glynn SA. Mesenchymal stem cells: key players in cancer progression. Mol Cancer. 2017; 16: 31. 10.1186/s12943-017-0597-8. 28148268 PMC5286812 · DOI
  72. [74]Mishra PJ, Mishra PJ, Glod JW, Banerjee D. Mesenchymal stem cells: flip side of the coin. Cancer Res. 2009; 69: 1255– 8. 10.1158/0008-5472.CAN-08-3562. 19208837 · DOI
  73. [76]Ghasemi Darestani N, Gilmanova AI, Al-Gazally ME, Zekiy AO, Ansari MJ, Zabibah RS, Jawad MA, Al-Shalah SAJ, Rizaev JA, Alnassar YS, Mohammed NM, Mustafa YF, Darvishi M, Akhavan-Sigari R. Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment. Cell Commun Signal. 2023; 21: 43. 10.1186/s12964-022-01012-0. 36829187 PMC9960453 · DOI
  74. [77]Maličev E, Jazbec K. An Overview of Mesenchymal Stem Cell Heterogeneity and Concentration. Pharmaceuticals (Basel). 2024; 17: 350. 10.3390/ph17030350. 38543135 PMC10975472 · DOI
  75. [78]Tian Y, Fang J, Zeng F, Chen Y, Pei Y, Gu F, Ding C, Niu G, Gu B. The role of hypoxic mesenchymal stem cells in tumor immunity. Int Immunopharmacol. 2022; 112: 109172. 10.1016/j.intimp.2022.109172. 36087506 · DOI

Cited by

Sorted by citations

Authors
Minev, T., Balbuena, S., Gill, J. M., Marincola, F. M., Kesari, S., & Lin, F.
Affiliations
  • CureScience (US)
  • Sonata Therapeutics, Boston, MA 02472, USA
  • Saint John's Health Center (US)
Corresponding author
Lin, Feng
ORCID
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2024-11-22
Volume
15
Issue
1
Pages
793-805
ISSN
1949-2553 (ISSN-L)
DOI
10.18632/oncotarget.28672
PMC
PMC11584032
OpenAlex
W4404634563
Cited by
34
References
3
Citations by year
2026: 12 · 2025: 20 · 2024: 2
FWCI
2.58
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Oncotarget (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
mesenchymal stem cells, cancer immunotherapy, tumor homing, tumor microenvironment, genetic engineering of stem cells, drug delivery, oncolytic viruses, immunomodulation, precision oncology
MeSH terms
Animals, Humans, Immunotherapy, Neoplasms, Mesenchymal Stem Cell Transplantation, Tumor Microenvironment, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review